BioCardia, Inc. (BCDA) is a Biotechnology company in the Healthcare sector, currently trading at $1.19. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: BCDA trades at a trailing Price-to-Earnings (P/E) of -1.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.08.
Net income is $8M (loss), growing at +10.2%/yr. Net profit margin is 0% (thin). Gross margin is -7463.8% (-6683.5 pp trend).
Balance sheet: total debt is $528,000 against $895,000 equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 1.12 (adequate). Debt-to-assets is 15.5%. Total assets: $3M.
Analyst outlook: 4 / 5 analysts rate BCDA as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 0/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).
